Literature DB >> 23337836

Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).

Vanessa Roldán1, Francisco Marín, Hermógenes Fernández, Sergio Manzano-Fernández, Pilar Gallego, Mariano Valdés, Vicente Vicente, Gregory Y H Lip.   

Abstract

Renal dysfunction is highly prevalent among patients with atrial fibrillation (AF) and confers an increased risk of thrombotic and bleeding complications. We evaluated the effect of renal function on prognosis in anticoagulated patients with AF and assessed the changes in renal function during a long-term follow-up period. We recruited 978 consecutive stable anticoagulated patients with AF from our outpatient anticoagulation clinic (international normalized ratio 2.0 to 3.0 within the previous 6 months). The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation at inclusion and 2 years of follow-up. Adverse events were recorded during follow-up (thrombotic/vascular events, major bleeding episodes, and mortality). Longitudinal changes in renal function were analyzed in 886 patients (90.6%). At baseline, the median eGFR using the Modification of Diet in Renal Disease equation was 70.24 ml/min/1.73 m(2) (interquartile range 46.79 to 72.52). During follow-up, a low eGFR was associated with thrombotic/vascular events, with every 30 ml/min/1.73 m(2) eGFR decrease (hazard ratio 1.42, 95% confidence interval [CI] 1.11 to 1.83, p = 0.006), bleeding (hazard ratio 1.44, 95% CI 1.08 to 1.94, p = 0.015), and mortality (hazard ratio 1.47, 95% CI 1.13 to 1.91, p = 0.004). After excluding patients with a baseline eGFR <30 ml/min/1.73 m(2), the mean eGFR in our cohort decreased >10 ml/min/1.73 m(2) in 181 patients (21%) during the follow-up period. The variables associated with severe renal impairment during follow-up were heart failure (odds ratio 3.58, 95% CI 1.36 to 9.42, p = 0.010), basal eGFR (odds ratio 6.34, 95% CI 2.44 to 16.50, p <0.001), and CHADS2 (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, and previous Stroke or transient ischemic attack [doubled]) score (odds ratio 1.63, 95% CI 1.19 to 2.23, p = 0.003). In conclusion, the presence of impaired renal function was closely related to thrombotic/vascular events, bleeding, and mortality in anticoagulated patients with AF. During follow-up, 1/5 of the patients had significant impairment in renal function. Importantly, normal or mild renal dysfunction at baseline did not exclude the subsequent development of severe renal dysfunction during the follow-up period. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23337836     DOI: 10.1016/j.amjcard.2012.12.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  24 in total

1.  Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Koji Miyamoto; Takeshi Aiba; Shoji Arihiro; Makoto Watanabe; Yoshihiro Kokubo; Kohei Ishibashi; Sayako Hirose; Mitsuru Wada; Ikutaro Nakajima; Hideo Okamura; Takashi Noda; Kazuyuki Nagatsuka; Teruo Noguchi; Toshihisa Anzai; Satoshi Yasuda; Hisao Ogawa; Shiro Kamakura; Wataru Shimizu; Yoshihiro Miyamoto; Kazunori Toyoda; Kengo Kusano
Journal:  Heart Vessels       Date:  2015-08-15       Impact factor: 2.037

2.  Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation.

Authors:  Qinmei Xiong; Gregory Y H Lip
Journal:  Curr Treat Options Neurol       Date:  2015-02       Impact factor: 3.598

3.  Renal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs re-expressed 4 variable modification of diet in renal disease.

Authors:  Rami Riziq-Yousef Abumuaileq; Emad Abu-Assi; Andrea López-López; Sergio Raposeiras-Roubin; Moisés Rodríguez-Mañero; Luis Martínez-Sande; Francisco Javier García-Seara; Xesus Alberte Fernandez-López; Jose Ramón González-Juanatey
Journal:  World J Cardiol       Date:  2015-10-26

4.  Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study.

Authors:  Daniele Pastori; Evaristo Ettorre; Gregory Y H Lip; Angela Sciacqua; Francesco Perticone; Francesco Melillo; Cosmo Godino; Rossella Marcucci; Martina Berteotti; Francesco Violi; Pasquale Pignatelli; Mirella Saliola; Danilo Menichelli; Marco Antonio Casciaro; Vito Menafra
Journal:  Br J Clin Pharmacol       Date:  2020-06-07       Impact factor: 4.335

5.  Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?

Authors:  Sérgio Barra; Rui Providência; Catarina Faustino; Luís Paiva; Andreia Fernandes; António Leitão Marques
Journal:  J Atr Fibrillation       Date:  2013-10-31

6.  Oxidized Low-Density Lipoprotein Predicts the Development of Renal Dysfunction in Atrial Fibrillation.

Authors:  Marija Polovina; Ivana Petrović; Voin Brković; Milika Ašanin; Jelena Marinković; Miodrag Ostojić
Journal:  Cardiorenal Med       Date:  2016-09-16       Impact factor: 2.041

Review 7.  Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.

Authors:  Peter Brønnum Nielsen; Deirdre A Lane; Lars Hvilsted Rasmussen; Gregory Y H Lip; Torben Bjerregaard Larsen
Journal:  Clin Res Cardiol       Date:  2014-11-22       Impact factor: 5.460

8.  Glomerular filtration rate: A prognostic marker in atrial fibrillation-A subanalysis of the AntiThrombotic Agents Atrial Fibrillation.

Authors:  Riccardo Proietti; Lucio Gonzini; Giovanni Pizzimenti; Antonietta Ledda; Pietro Sanna; Ahmed AlTurki; Vincenzo Russo; Mauro Lencioni
Journal:  Clin Cardiol       Date:  2018-12-04       Impact factor: 2.882

9.  Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants.

Authors:  Geoffrey D Barnes; Brahmajee K Nallamothu; Anne E Sales; James B Froehlich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-03-01

Review 10.  Stroke prevention strategies in high-risk patients with atrial fibrillation.

Authors:  Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip
Journal:  Nat Rev Cardiol       Date:  2020-10-27       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.